Epidemiology of NAFLD in China Jian-Gao Fan MD, PhD.

Size: px
Start display at page:

Download "Epidemiology of NAFLD in China Jian-Gao Fan MD, PhD."

Transcription

1 Epidemiology of NAFLD in China Jian-Gao Fan MD, PhD. Professor and Director Department of Gastroenterology Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai , China

2 Epidemiological studies in FLD Case definition Liver biopsy CT scan Ultrasound FibroScan/FibroTouch FLI, HSI Sampling frame Population Community Clinical based Hospital based --Consecutive/Non-consecutive

3 Ultrasound of fatty liver

4 Fatty liver in given specific Chinese population Labor workers in Daqing, Liaonin (n=4100): 5% Labor workers in Beijing (n=1050): 11% Employees in Shaoxing, Zhejiang (n=11372): 10% White collars in Beijing (n=818): 18% White collars in Shanghai (n=4009): 13% Among 6553 employees in Lianyungang, Jiangsu: retired cadre 10%, policemen 9%, clerk 6%, workmen 4% Fan JG. Review. Shijie Huaren Xiaohua Zazhi 2001;9:6-10.

5 Increased prevalence of fatty liver in China City Period Subjects Trend *Beijing Administrative officers 23% to 26% Shanghai Factory workers 4% to 14% Wuhan Office workers 12.5% to 24.5% Fan JG, JGH 2007;22: Wang Z. Postgrad Med J 2007;83: * unpublished

6 Increased prevalence of FL in Shanghai factory workers between 1995 and % 50% 40% 30% 20% 10% 0% Fatty liver Habitual drinking FL/Abnormal ALT Obesity Daibetes Hypertension Hyper-TG Hyper-TC Fan JG, et al. J Gastroenterol Hepatol 2007;22:

7 Consensus of management of FLD by Chinese Society of Medicine Guideline for the diagnosis of NAFLD and ALD. Chin J Hepatol 2001 & 2003 Guidelines for diagnosis and treatment of NAFLD & ALD. J Dig Dis 2008; 9: Chinese Guidelines for diagnosis and management of NAFLD & ALD: update J Dig Dis 2011; 12:

8 Definition of NAFLD There is evidence of hepatic steatosis, either by imaging or by histology, and no causes for secondary steatosis. NAFLD is a highly prevalent form of FLD caused by over-nutrition. NAFLD is an acquired metabolic stressinduced liver diseases associated with insulin resistance and genetic susceptibility.

9 Fatty liver in general population in China City/Year Prevalence Etiology Others Shanghai/ % AFL 0.8%, NAFL 15% Other 1.2% Guangzhou/ % AFL 0.5%, NAFL 11.7% Other 1.8% Drinking 13% Children 1.3% Xi an/ % AFL 8.7% (?), NAFL 14.7% Drinking 66% Chengdu/ % AFL 2.6%, NAFL 6.3% Other 3.6% Beijing/ % AFL 4.1%, NAFL 31.3% Shanghai/ /8810 (40-70 yrs in Chongming Island) NAFLD 42.2% 27.6% in NGT, 45.7% in pre-diabetes, 62.5% in diabetes persons Fan, J Hepatol 2005; 43: Zhou, WJG 2007;13: Yan, Hepatol Int 2008; 2:S86-S87. Li, HBPD Int. 2009;8: Yan, JGH; 2013, 28: Yang Z, Sci Rep. 2016;6:37886.

10 Prevalence of Fatty Liver in Shanghai Adults Total 17% Male 19% Female 15% 5% 7% AFL Mixed FL NAFLD 15% AFL 0.8% Mixed FL 1.2% NAFLD 88% Fan JG, et al. J Hepatol 2005; 43:

11 Criteria for obesity and MetS Only 2-3% of Asians classified as obesity by Western criteria. ethnic differences All Asian populations studied had a higher BF% at a lower BMI compared to Caucasians For the same BF%, their BMI was 3-5 units lower compared to Caucasians.

12 Modified definition for Asians Three or more of the following: Central obesity and/or obesity: Waistline >90 cm (M), >80 cm (F) and/or BMI > 25 kg/m 2 Hypertriglyceridaemia: TG 1.7 mmol/l Low HDL-C: <1.03 mmol/l (M), <1.29 mmol/l (F) High blood pressure: 130/85 mmhg. High fasting glucose: FPG 6.1 mmol/l. Fan JG & Pen YD. HBPT Int 2007

13 Fan JG, World J Gastroenterol, 2008; 14:

14 Prevalence of NAFLD/NASH in Shanghai Prevalence of fatty liver and the metabolic syndrome(%) Fatty liver Metabolic syndrome Both prevalence of MetS and NAFLD was 15.3% in Shanghai adults in In NAFLD, prevalence of MetS and abnormal ALT was 52.9% and 12.7%, respectively. Prevalence of NASH might be between 1.9% and 4.1% in Shanghai adults BMI<23 BMI BMI>=25 Fan JG, J Gastroenterol Hepatol 2005 with some data unpublished

15 Prevalence of Lean NAFLD Lean NAFLD is more common in Asia Prevalence of Lean NAFLD in General Population Proportion of Lean NAFLD over all NAFLD USA (Younossi 2012) KOREA (Cho HC 2016) KOREA (Kim HJ 2004) INDIA (Das K 2010) China (Fan 2007)

16 Prevalence of NASH in Shanghai Bao-Steel Company A total of employees of Shanghai Bao-Steel Company were undergone biannual health check-up. Prevalence of abnormal ALT was 4.6%, without obvious changes between 1995 and Prevalence of fatty liver in patients with abnormal ALT was increased between from 25.9% to 51.4%. Prevalence of NAFLD among subjects was 13.1% in 2002, percentage of abnormal ALT among NAFLD patients was 16.4%. Prevalence of NASH might be around 2.2% in health check-up adults in Fan JG, J Gastroenterol Hepatol 2007 with some data unpublished

17 Incidence of NAFLD in Shanghai 5,226 non-drinking workers without US-fatty liver at baseline. After 2-year follow-up, 310 pts (6.2%) were found to have NAFLD. Incidence of NAFLD (3 new cases/100 people/ year) is equal to that in Dionysos study. The baseline BMI, serum triglyceride and their subtle gain during follow-up were independent predictors of incident of NAFLD. Fan JG, et al. Hepatol International, 2010

18 Impact of BMI on incidence and remission of NAFLD < > 30 Incidence of FL Changes of BMI with FL Changes of BMI without FL < > 30 Remission rate of FL Changes of BMI with FL remission Changes of BMI persistent with FL 13.6% (60/440) NAFLD was recovery at the end of 2-year follow-up. Zhou C Fan JG. Chin J Intern Med Chin J Hepatol 2010

19 Increased prevalence of obesity in Asia 8% 7% 6% 5% 4% 3% 2% China Japan Korea India Indonesia 1% 0% Year Fan JG, et al. J Hepatol 2017

20 Global prevalence of NAFLD Younossi Z, et al. Gastroenterology.2016;150:

21 Wang FS, Fan JG, et al. Hepatology 2014; 60:

22 Etiology of fatty liver in liver clinic in Shanghai 6.4% 7.2% 8.3% Non-alcoholic Alcoholic Virus hepatitis Miscellous % 90.00% 80.00% 70.00% 60.00% 50.00% 40.00% 30.00% Percent of abnormal ALT Percent 78.1% 20.00% 10.00% 0.00% NAFLD AFL HBV with FL DILI-FL Percent of NASH might be 20% in out-patients with NAFLD. Fan JG, et al. Shanghai Med J, 1998;21:68-70

23 Liver biopsy from 11 year old male with abnormal LFTs

24 Histological changes in 152 Chinese pts with NAFLD 100% % 60% 40% 20% 0% steatosis(1/2/3) ballonning degeneration (y/n) NAS(1-3;3-4;5) fibrosis(0-4) Male 73.8%, Age :37±10 yrs, BMI: 26±3 kg/m 2 Percent of NASH in biopsy-proven NAFLD was 41.4%. Advanced fibrosis was 15.8%, associated with MetS and severe inflammation. Xun YH, Fan JG, et al. J Dig Dis, 2012; 13:

25 Histological changes of 101 patients with NAFLD Characteristics NAFLD (n=101) None-NASH (n=15) Borderline NASH (n=32) Definitive NASH (n=54) P Steatosis grade,n (%) <0.001 S1 (5-33%) 32 (31.7) 15 (100) 15 (46.9) 2 (3.7) S2 (34-66%) 45 (44.6) 0 17(53.1) 28(51.9) S3 (>66%) 24 (23.8) (44.4) Fibrosis stage, n (%) <0.001 F0 18 (17.8) 7(46.7) 9(28.1) 2(3.7) F1 44 (43.6) 5(33.3) 21(65.6) 18(33.3) F2 26 (25.7) 1(6.7) 1(3.1) 24(44.4) F3 10 (9.9) 2 (13.3) 1(3.1) 7(13.0) F4 3 (3.0) (5.6) Percent of NASH and cirrhosis was 54% and 3%, respectively Both were associated with T2DM and MetS. Shen F, Fan JG. Liver Int 2015; 35:

26 Study profile of NAFLD across the Asia Pacific region the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:

27 Percentage of patients with NASH by country the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:

28 Percentage of patients with advanced fibrosis by country the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:

29 Independent factors discriminating the different histological subgroups the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:

30 Natural history of NAFLD according to data from Asia Annual incidence of NAFLD 3-4% 60% can reverse NAFLD by lifestyle intervention 25% progress from NAFL to NASH and have fibrosis progression in 3 yrs Spontaneous reversal of NASH uncommon without intervention Fibrosis progression 1 stage in 7 yrs in NASH; 1 stage in 14 yrs in NAFL No data on reversal of cirrhosis Normal liver NAFL NASH ± fibrosis Cirrhosis Absence of cirrhosis reported in 30-50% of NAFLD-associated HCC in Asians The absolute risk of HCC in noncirrhotic patients is <0.1% per year HCC 1-4% per year Fan JG, Kim SU, Wong WS. J Hepatol 2017

31 NAFLD leads to liver cancer: do we have sufficient evidence? Duan XY, Qiao L, Fan JG. Cancer letter 2014

32 32

33 80% 70% 60% 50% 40% 30% 20% 10% 0% Obesity Hypertension High TG high TC Diabetes MetS NAFLD n=358 Controls n=788 80% 70% 60% 50% 40% 30% 20% 10% 0% hypertension high TG high TC Diabetes FL with Obesity n=274 FL without Obesity n=84 Obesity alone n=174 Nor FL or obesity n=614 Fan JG, et al. JGH 2007;22:

34 上海宝钢队列糖尿病发病率与危险度比 基线特征 DM 发病数 DM 发病率 (%) 危险度比 (HR) N=12438,follow-up 6 years 95% CI 下限 95% CI 上限 肥胖 BMI <25 kg/m BMI 25 kg/m IFG (-) (+) 高 TG 血症 (-) (+) 高 TC 血症 (-) (+) 脂肪肝 (-) (+) 高 Hb 血症 (-) (+) Fan JG, et al. J Diabetes Investig. 2016; 7:

35 上海崇明脂肪肝流行病学调查 Circulating periostin in relation to insulin resistance and NAFLD among overweight and obese subjects. Sci Rep. 2016;6: Plasma selenium levels and NAFLD in Chinese adults: a cross-sectional analysis. Sci Rep. 2016; 6: Plasma osteoprotegerin levels are inversely associated with NAFLD in patients with type 2 diabetes: A case-control study in China. Metabolism. 2016; 65(4): Association of calf circumference with insulin resistance and NAFLD: the REACTION study. BMC Endocr Disord. 2017;17(1):28. Impaired lung function is associated with NAFLD independently of metabolic syndrome features in middle-aged and elderly Chinese. BMC Endocr Disord. 2017; 17(1):18.

36 Fatty liver & HBV infection in Chinese Inverse association between HBsAg+ve and ultrasound-diagnosed fatty liver both in Shanghai and Taipei. Fan JG, et al. World J Gastroenterol Cheng YL, et al. Plos One 2013 Inverse association between HBV infection and MRS-diagnosed fatty liver in Hong Kong adults. Wong VWS, et al. J Hepatol 2012 Inverse association between HBV infection and hypertriglyceridemia and MetS. Luo et al. Clin Chim Acta. 2007; Jan et al. Int J Obes 2006; Wong et al. J Hepatol 2012

37 Ye DW, Fan JG, et al.aasld,2009

38 Fan JG, et al. AASLD 2016

39 Fatty liver & CHB in Our Group 1 Hepatitis B and fatty liver: causal or coincidental? J Gastroenterol Hepatol. 2008; 23(5): Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with CHB infection. J Gastroenterol Hepatol. 2008; 23: Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model. J Gastroenterol Hepatol. 2012; 27: Hepatic Steatosis Is Highly Prevalent in CHB Patients and Negatively Associated with Virological Factors. Dig Dis Sci. 2014; 59: Saturated fatty acid Inhibits Viral Replication in HBV Infection with NAFLD by TLR4 Mediated Innate Immune Response. Hepat Mon. 2015; 15:e CAP for noninvasive assessment of hepatic steatosis using Fibroscan: Validation in chronic hepatitis B. Dig Dis Sci 2015; 60: Thyroid function is associated with NAFLD in chronic hepatitis B infected subjects. J Gastroenterol Hepatol. 2015; 30: Linked polymorphisms of PNPLA3 confer susceptibility to NASH and decreased viral load in chronic hepatitis B. World J Gastroenterol. 2015; 21: PNPLA3 rs predisposes CHB to hepatic steatosis, but improves insulin resistance and glucose metabolism. J Diabetes Res. 2017; 2017: Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with NAFLD and CHB. Sci Rep. 2017, 7:10517.

40 What are the settings for NAFLD? Overweight/Central obesity 50% Steatosis 10%-40% Steatohepatitis 50% Liver fibrosis 15%~30% Cirrhosis & HCC 30%~40% MetS T2DM Cancer & CVD Liver-related mortality Patrick L. Altern Med Rev, 2002, 7: Fan JG. JGH, 2007;22: JDD 2008;9:63-70

41 NAFLD is not just a Western problem Prevalence of fatty liver increased rapidly in past decades with obesity and MetS pandemic in China. Fatty liver is more often associated with obesity than with alcoholism. Chronic HBV infection do not account for increased trend of fatty liver and fatty liver increased in CHB as well. Cardiovascular and diabetic risk may compete with liver disease-related risk in dictating the final outcome. NAFLD is emerging into a new and major health problem in Chinese. Fan JG. J Hepatol 2009; JGH 2013.

42 Thanks for for your attention!

At Least 1 in 5 Patients in Your Practice Have Fatty Liver

At Least 1 in 5 Patients in Your Practice Have Fatty Liver At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease

More information

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-

More information

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the

More information

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary

More information

Improving Access to Quality Medical Care Webinar Series

Improving Access to Quality Medical Care Webinar Series Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

La sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV

La sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV WORKSHOP HCV: la guarigione e il parallelismo tra risposta virologica sostenuta e outcome clinico Milano, 25 Ottobre 2018 Ospedale San Raffaele IRCCS - Sede Turro La sindrome metabolica e il suo impatto

More information

AASLD Immune tolerant phase HBV NAFLD diagnostic HCC

AASLD Immune tolerant phase HBV NAFLD diagnostic HCC AASLD 2016 Immune tolerant phase HBV NAFLD diagnostic HCC Immune tolerant 3 Modified from Chan HLY and Wong VWS. Hepatitis B. In Zakim and Boyers s Hepatology 2012 2015 AMERICAN ASSOCIATION FOR THE S1T6UDY

More information

UMHS-PUHSC JOINT INSTITUTE

UMHS-PUHSC JOINT INSTITUTE Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,

More information

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based

More information

Screening for HCCwho,

Screening for HCCwho, Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology

More information

Transient elastography in chronic liver diseases of other etiologies

Transient elastography in chronic liver diseases of other etiologies 4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia

More information

Downloaded from zjrms.ir at 3: on Monday February 25th 2019 NAFLD BMI. Kg/m2 NAFLD

Downloaded from zjrms.ir at 3: on Monday February 25th 2019 NAFLD BMI. Kg/m2 NAFLD logistic regression Student s t-test P< BMI BMI P< ALT AST P< Email:mkhoshbaten@yahoo.com Kg/m2 NASH RUQ B C II Case-Control II Logistic Regression Chi-Square T-test P< Grade Model 1- A diffuse hyper echoic

More information

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy

More information

Does Viral Cure Prevent HCC Development

Does Viral Cure Prevent HCC Development Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,

More information

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal

More information

NAFLD & NASH: Russian perspective

NAFLD & NASH: Russian perspective NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received

More information

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence

More information

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%

More information

The place of bariatric surgery in NASH: can we extend the indications? - No

The place of bariatric surgery in NASH: can we extend the indications? - No The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the

More information

PREVALENCE OF NAFLD & NASH

PREVALENCE OF NAFLD & NASH - - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)

More information

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none

More information

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic

More information

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute

More information

Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010

Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010 doi: 10.1111/j.1751-2980.2010.00476.x Consensus report Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010 (Published in Chinese on Chinese Journal of Hepatology

More information

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012 NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat

More information

American Journal of Oral Medicine and Radiology

American Journal of Oral Medicine and Radiology American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE AMONG TYPE 2 DIABETIC POPULATION

More information

Clinical dilemmas in HBeAg-negative CHB

Clinical dilemmas in HBeAg-negative CHB Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department

More information

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London Fatty liver- how important is it? Importance in terms of: Prevalence Pathogenesis

More information

White Nights of Hepatology 2016

White Nights of Hepatology 2016 White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow

More information

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;

More information

Non-alcoholic fatty liver disease (NAFLD) is a

Non-alcoholic fatty liver disease (NAFLD) is a Original Article / Liver Hepatobiliary & Pancreatic Diseases International The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population Shou-Wu Lee, Teng-Yu Lee,

More information

Zhang, Q; Wong, CKH; Kung, K; Chan, JCY; Sy, TWB; Lam, M; Xu, XG; Yang, MF; Yu, Y; Lin, XP; Lam, CLK

Zhang, Q; Wong, CKH; Kung, K; Chan, JCY; Sy, TWB; Lam, M; Xu, XG; Yang, MF; Yu, Y; Lin, XP; Lam, CLK Title Development and validation study of a non-alcoholic fatty liver disease risk scoring model among adults in China Author(s) Zhang, Q; Wong, CKH; Kung, K; Chan, JCY; Sy, TWB; Lam, M; Xu, XG; Yang,

More information

NAFLD/NASH in Sub- Saharan Africa

NAFLD/NASH in Sub- Saharan Africa NAFLD/NASH in Sub- Saharan Africa Corné Kruger Gastroenterologist Durbanville Mediclinic Cape Town Liver Interest group meeting: Cape Town 2015 Introduction NAFLD is the most common liver disease disease

More information

HEP DART 2017, Kona, Hawaii

HEP DART 2017, Kona, Hawaii HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George

More information

Treatment of HCC in real life-chinese perspective

Treatment of HCC in real life-chinese perspective Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA

More information

Cornerstones of Hepatitis B: Past, Present and Future

Cornerstones of Hepatitis B: Past, Present and Future Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

Natural History of Chronic Hepatitis B

Natural History of Chronic Hepatitis B Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,

More information

METABOLIC SYNDROME AND HCV: FROM HCV

METABOLIC SYNDROME AND HCV: FROM HCV METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,

More information

The Impact of HBV Therapy on Fibrosis and Cirrhosis

The Impact of HBV Therapy on Fibrosis and Cirrhosis The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for

More information

Screening cardiac patients for advanced liver disease

Screening cardiac patients for advanced liver disease HKASLD 30 th ASM and International Symposium on Hepatology 2017 Screening cardiac patients for advanced liver disease 5 Nov 2017 Dr. Lau Yue Leung Joulen Pamela Youde Nethersole Eastern Hospital NAFLD

More information

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem

More information

Understanding your FibroScan Results

Understanding your FibroScan Results PATIENT & CAREGIVER EDUCATION Understanding your FibroScan Results This information will help you understand your FibroScan results. About FibroScan FibroScan is a specialized ultrasound machine for your

More information

NASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014

NASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014 NASH : Diagnosis and investigation VII Workshop international, Curitiba, Brazil 29/08/2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France Usual diagnostic circumstances

More information

Paris Hepatology Conference PROGNOSIS OF NASH

Paris Hepatology Conference PROGNOSIS OF NASH Paris Hepatology Conference PROGNOSIS OF NASH Palais des Congrès Monday 15th January 2018 14:45-15:00 PHC 2018 - www.aphc.info Driven to care Disclosures Advisory committees Speaking and teaching Research

More information

The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University

The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and

More information

Association between metabolic syndrome and the development of non-alcoholic fatty liver disease

Association between metabolic syndrome and the development of non-alcoholic fatty liver disease EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 77-84, 2013 Association between metabolic syndrome and the development of non-alcoholic fatty liver disease YI WANG 1, YU YUAN LI 2, YU QIANG NIE 2, YONG JIAN ZHOU

More information

WORLDWIDE EPIDEMIOLOGY OF NASH

WORLDWIDE EPIDEMIOLOGY OF NASH WORLDWIDE EPIDEMIOLOGY OF NASH Stefano Bellentani, M.D., Ph.D. Chief of Gastroenterology and Hepatology Service Clinica Santa Chiara Locarno Switzerland & Fondazione Italiana Fegato (FIF), Bassovizza (Trieste),

More information

Natural History of HBV Infection

Natural History of HBV Infection Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2

More information

«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin

«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin «STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic

More information

NIH Public Access Author Manuscript Am J Med Sci. Author manuscript; available in PMC 2015 January 01.

NIH Public Access Author Manuscript Am J Med Sci. Author manuscript; available in PMC 2015 January 01. NIH Public Access Author Manuscript Published in final edited form as: Am J Med Sci. 2014 January ; 347(1):. doi:10.1097/maj.0b013e31828b25a5. Association Between Metabolic Syndrome and Its Individual

More information

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare 6 Riunione Monotematica A.I.S.F. 2015 NASH malattia epatica, oncologica e cardiovascolare Modena, 9 ottobre 2015 Massimo Colombo NAFLD e HCC: caratteristiche distintive Chairman Department of Liver, Kidney,

More information

/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT

/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT 原 著 29 34-41, 2014 FIB4 Index 1 1 1 1 2 1 1 FIB4 Index FIB4 Index cut off 2.67 2.67 12,059 FIB4 IndexFIB4 Index 2.67 / FIB4 Index AST ALT FIB4 Index 2.67 161 1.3% FIB4 Index 5 FIB4 Index 1.1 5 1.6 FIB4

More information

Internal and Emergency Medicine Official Journal of the Italian Society of Internal Medicine. ISSN Volume 8 Number 3

Internal and Emergency Medicine Official Journal of the Italian Society of Internal Medicine. ISSN Volume 8 Number 3 Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study Arrigo F. G. Cicero,

More information

Diseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic

Diseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Diseases to Watch Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) - Prevalence and Symptoms - Risk Factors and Potential treatments - Target identification for NASH Robert

More information

What is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob

What is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:

More information

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general

More information

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis

More information

Bariatric Surgery and Liver Transplantation

Bariatric Surgery and Liver Transplantation Bariatric Surgery and Liver Transplantation Sammy Saab, MD, MPH, AGAF, FACG, FAASLD Professor of Medicine and Surgery Head, Outcomes Research in Hepatology David Geffen School of Medicine at UCLA Disclosures

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C

More information

Laboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011

Laboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011 Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled

More information

Metabolic Syndrome and HCC. Jacob George

Metabolic Syndrome and HCC. Jacob George Metabolic Syndrome and HCC Jacob George MetS and risk of HCC and ICC All with HCC and ICC between 1993 and 2005 identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. For

More information

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif Non alcoholic fatty liver and Non alcoholic Steatohepatitis By Dr. Seham Seif Definition NAFL describe a common clinicopathological conditions characterized by significant lipid deposition in the hepatocytes

More information

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient

More information

NASH PROGRESS IN THE LAST DECADE

NASH PROGRESS IN THE LAST DECADE PROGRESS IN THE LAST DECADE Mitchell L. Shiffman, MD, FACG Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need A GLOBAL HEALTH PROBLEM Nigeria Australia Spain

More information

STOP Hepatocellular Carcinoma

STOP Hepatocellular Carcinoma STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern

More information

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic

More information

Bio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis

Bio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis AASLD 2015 /FibroSure Scientific Publications Section 1 - compared to APRI, FIB-4 and transient elastography Houot 2015, TE, FIB-4, APRI Meta-analysis is superior to TE by Fibroscan, APRI and Fib-4 using

More information

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams

More information

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,

More information

NAFLD and NASH: The Not-So-New Kids on the Block

NAFLD and NASH: The Not-So-New Kids on the Block NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an

More information

PEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 REVIEW

PEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 REVIEW PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)

More information

Transient elastography in chronic viral liver diseases

Transient elastography in chronic viral liver diseases 4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN ASIAN-PACIFIC REGION

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN ASIAN-PACIFIC REGION SL 2-1 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN ASIAN-PACIFIC REGION Mikio KAJIHARA 1,3, Yoshinori HORIE 2,3, Hiromasa ISHII 3 1 Tokyu Hospital, 2 Eiju General

More information

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,

More information

Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Type 2 Diabetes Mellitus Patients in Rajshahi Medical College Hospital

Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Type 2 Diabetes Mellitus Patients in Rajshahi Medical College Hospital WELCOME Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Type 2 Diabetes Mellitus Patients in Rajshahi Medical College Hospital Presented by DR. PRABIR MOHAN BASAK ASSISTANT PROFESSOR DEPARTMENT

More information

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently

More information

Alimentary Pharmacology and Therapeutics SUMMARY. Background Metabolic syndrome is a known risk factor of cirrhosis in chronic hepatitis B (CHB).

Alimentary Pharmacology and Therapeutics SUMMARY. Background Metabolic syndrome is a known risk factor of cirrhosis in chronic hepatitis B (CHB). Alimentary Pharmacology and Therapeutics Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B a prospective cohort study with paired transient

More information

Management of Chronic Hepatitis B in Asian Americans

Management of Chronic Hepatitis B in Asian Americans Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,

More information

Currently status of HBV therapy: efficacy and limitations

Currently status of HBV therapy: efficacy and limitations 9 November 2016 Currently status of HBV therapy: efficacy and limitations Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of

More information

tage Percent Total & over Total & over Men Women Men Women

tage Percent Total & over Total & over Men Women Men Women Paul Angulo, MD, FACG, AGAF Professor of Medicine, Section Chief of Hepatology Division i i of Digestive i Diseases and Nutrition i University of Kentucky Medical Center Lexington, KY Paul Angulo, MD University

More information

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at: ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis

More information

Association of serum adipose triglyceride lipase levels with obesity and diabetes

Association of serum adipose triglyceride lipase levels with obesity and diabetes Association of serum adipose triglyceride lipase levels with obesity and diabetes L. Yang 1 *, S.J. Chen 1 *, G.Y. Yuan 1, L.B. Zhou 2, D. Wang 1, X.Z. Wang 1 and J.J. Chen 1 1 Department of Endocrinology,

More information

NAFLD: US GUIDELINES. US Guidelines for NAFLD

NAFLD: US GUIDELINES. US Guidelines for NAFLD NAFLD: US GUIDELINES Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University School of Medicine US Guidelines for NAFLD Represents consensus amongst AGA, AASLD and ACG

More information

HCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011

HCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011 HCC Prevention Jee-Fu Huang Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan TCC, HCC Prevention, 26 Nov, 2011 1 Outline Pathogenic and Risk Factors HBV HCV Primary Secondary Primary

More information

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine

More information

Patient Information Leaflet Non-Alcoholic Fatty Liver Disease (NAFLD) fatty-liver

Patient Information Leaflet Non-Alcoholic Fatty Liver Disease (NAFLD) fatty-liver Patient Information Leaflet Non-Alcoholic Fatty Liver Disease (NAFLD) fatty-liver Derriford Hospital Derriford Road Plymouth PL6 8DH Tel: 01752 431320 www.plymouthhospitals.nhs.uk 1 What is fatty liver?

More information

Disclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only

Disclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping

More information

Chronic Hepatitis B Infection

Chronic Hepatitis B Infection Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis

More information

How to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris

How to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris How to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris CLINICAL CASE 1996. 54 years old female Department of Primary CV Prevention

More information

Don t interfere My first choice is always nucs!

Don t interfere My first choice is always nucs! Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr

More information

Diabetes Liver Screen

Diabetes Liver Screen YOUR LIVER AND YOUR HEALTH Diabetes Liver Screen Non-Alcoholic Fatty Liver Disease (NAFLD) PROF. SUZANNE NORRIS www.liverwellness.ie The spectrum of non-alcoholic fatty liver disease Diabetes Liver Screen

More information

Identifying patients with chronic hepatitis B at high risk of type 2 diabetes mellitus: a cross-sectional study with pair-matched controls

Identifying patients with chronic hepatitis B at high risk of type 2 diabetes mellitus: a cross-sectional study with pair-matched controls Shen et al. BMC Gastroenterology (2015) 15:32 DOI 10.1186/s12876-015-0263-9 RESEARCH ARTICLE Open Access Identifying patients with chronic hepatitis B at high risk of type 2 diabetes mellitus: a cross-sectional

More information

Investigating general liver disease/transaminitis

Investigating general liver disease/transaminitis BHIVA Autumn Conference London 14 October 2016 Investigating general liver disease/transaminitis Emmanuel A. Tsochatzis Senior Clinical Lecturer and Consultant Hepatologist Institute for Liver and Digestive

More information